title: Rebound hypersecretion of GH following octreotide withdrawal due to liver dysfunction in an acromegalic patient.
abstract: Octreotide usually induces long-acting inhibition of GH secretion without rebound hypersecretion. We report a patient with acromegaly who showed rebound elevation of GH and insulin-like growth factor-1 (IGF-1) after octreotide withdrawal. The patient responded remarkably to octreotide therapy with normalization of GH and IGF-1 and shrinkage of pituitary macroadenoma. Octreotide therapy was stopped when he developed liver dysfunction. GH and IGF-1 were markedly elevated for two weeks after cessation of octreotide.
authors.affiliation: Clinical Research Institute, Kyoto National Hospital, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Shimatsu
authors.forename: H
authors.initials: H
authors.lastname: Murabe
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Usui
mesh_terms: D000172:Acromegaly / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006728:Hormones / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*
chemical_list: D006728:Hormones; D019382:Human Growth Hormone; D015282:Octreotide